Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Discrete Choice Experiment to Understand Patient Preferences for Self-Injectable Preventive Treatments for Migraine – A quantitative pilot
Headache
Headache Posters (7:00 AM-5:00 PM)
116
Self-injectable calcitonin gene-related peptide monoclonal antibodies for migraine prevention appear to have comparable safety and efficacy, such that administration aspects may be important for treatment selection.
To quantify the trade-offs people with migraine are willing to make between attributes of preventive treatments.
Adults from the US, the UK, and Germany with self-reported episodic or chronic migraine of at least moderate severity and experience with prescription preventive treatments participated in an online pilot discrete choice experiment (DCE). The DCE elicited preferences for seven device attributes identified from a targeted literature review and in-person focus groups: ‘dosing schedule’, ‘storage requirements’, ‘base and pinching’, ‘injection steps’, ‘injection duration’, ‘needle removal’, and ‘dose confirmation’. Participants chose between two administration devices described by these attributes and an oral alternative. Logit models were used to obtain relative attribute importance (RAI) and to predict the probability of patients’ preferences for autoinjector profiles.
304 participants (episodic migraine, 52.6%; female, 53.9%; mean age 42.0 years) completed the pilot DCE. Participants valued longer storage at room temperature (RAI: 37.2%), a shorter injection duration (RAI: 24.3%), needle auto-retraction (RAI: 19.6%), a wide autoinjector base (RAI: 8.1%), twisting to unlock (RAI: 5.4%), once-monthly injections (RAI: 2.7%) and dose confirmation via a 360-degree window (RAI: 2.7%). Based on elicited preferences for the considered attributes, a higher proportion of patients (47.2%) preferred an attribute profile comparable to galcanezumab over profiles comparable to erenumab (24.9%), fremanezumab once a month (14.3%), and fremanezumab every 3 months (13.6%).
Key drivers for device preferences were storage requirements, a short injection duration, needle auto-retraction, and a wide autoinjector base. Patients preferred a profile similar to galcanezumab over profiles of other self-injectable migraine preventive treatments. The preference information may enhance communication about potentially effective migraine preventive treatment options.
Authors/Disclosures
Jaein Seo (Evidera)
PRESENTER
Jaein Seo has received personal compensation for serving as an employee of Evidera.
Caitlin Thomas (Evidera) Caitlin Thomas has received personal compensation for serving as an employee of Evidera.
Tommi Tervonen (Evidera) Tommi Tervonen has received personal compensation for serving as an employee of Evidera.
Thibaud Prawitz (Evidera) Thibaud Prawitz has received personal compensation for serving as an employee of Evidera.
Janet Ford Janet Ford has received personal compensation for serving as an employee of Eli Lilly and Company . Janet Ford has received stock or an ownership interest from Eli Lilly and Company .
Virginia L. Stauffer Virginia L. Stauffer has received personal compensation for serving as an employee of Eli Lilly and Company. Virginia L. Stauffer has received stock or an ownership interest from Eli Lilly and company.
Robert A. Nicholson, PhD (Eli Lilly & Company) Dr. Nicholson has received personal compensation for serving as an employee of Eli Lilly & Company. Dr. Nicholson has stock in Eli Lilly & Company. Dr. Nicholson has received intellectual property interests from a discovery or technology relating to health care.
Kevin Duffy (Eli Lilly) Kevin Duffy has received personal compensation for serving as an employee of Eli Lilly.
Antje Tockhorn-Heidenreich Antje Tockhorn-Heidenreich has received personal compensation for serving as an employee of Eli Lilly and Company. An immediate family member of Antje Tockhorn-Heidenreich has received personal compensation for serving as an employee of Evidera. Antje Tockhorn-Heidenreich has received stock or an ownership interest from Eli Lilly and Company . An immediate family member of Antje Tockhorn-Heidenreich has received stock or an ownership interest from PPD.